Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03643861 · ClinicalTrials.gov registry record · NA

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

A NA study of Breast Cancer, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT03643861 is a NA study of Breast Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03643861, a NA study of Breast Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.

Conditions Studied

Interventions

  • RADIATION 5 Fraction Stereotactic Body Radiation Therapy

Study Locations (1)

Alabama

  • University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC) - Birmingham

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2019-08-20
Est. Completion 2028-12
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT03643861

The ClinicalTrials.gov registry entry for NCT03643861 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which 5 Fraction Stereotactic Body Radiation Therapy is the first listed.

NCT03643861 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT03643861 about?

NCT03643861 is a clinical study titled "RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)". This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.

What is the current status of trial NCT03643861?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2019-08-20. Estimated completion is 2028-12.

What conditions does trial NCT03643861 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03643861?

The interventions under investigation include: 5 Fraction Stereotactic Body Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT03643861?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03643861 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.